39 published articles in Preclinical Research
BPC-157 does stimulate nitric oxide (NO) production via eNOS upregulation and VEGFR2 signalling, but preclinical data consistently show it simultaneously suppresses free radical formation and reduces oxidative damage markers such as MDA. The apparent paradox resolves when the peptide's context-dependent NO modulation is distinguished from the cytotoxic NO overproduction it is specifically documented to attenuate.
Cycling GH peptides to preserve endogenous production depends on the receptor class being targeted. GHRH-receptor agonists (sermorelin, tesamorelin, CJC-1295) carry minimal suppression risk because they amplify pulsatile secretion through the same pathway the hypothalamus uses. GHS-R1a agonists (GHRPs, ipamorelin, MK-677) carry a receptor-desensitisation risk that structured off-periods can partially mitigate.
As of 2026, no completed randomised controlled trial has evaluated BPC-157 specifically in human rotator cuff tears. The evidence base consists of one direct rat rotator cuff model, multiple preclinical tendon-healing studies, and two recent narrative reviews. A Phase 2 RCT in a related musculoskeletal indication (hamstring strain, NCT07437547) is registered but unpublished.